Inside Precision Medicine May 22, 2024
Chris Anderson

The results of two back-to-back randomized double-blind placebo controlled trials has shown that a 100-year-old vaccine originally developed to prevent tuberculosis helps protect people with type 1 diabetes from COVID-19 and other infectious diseases. The research by investigators at the Massachusetts General Hospital (MGH) found that the Bacillus Calmette-Guérin (BCG) vaccine provided continuous protection against all the viral variants for almost the entire COVID-19 pandemic.

The results of the 18-month trial are published today in iScience. The Phase III trial was conducted later in the pandemic when the Omicron variant was circulating in the population. An earlier Phase II trial was conducted earlier in the pandemic, and those results were published in the journal Cell Reports Medicine.

“Individuals with type...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Trends
Inside the controversy over FDA's recent gene therapy approval
Novo Nordisk eyes another Ozempic approval by January
New drug cuts cardiovascular events, death by 36%
Doctors support growth of at-home testing, survey finds, opening new avenues for biopharma patient outreach
Our 4 biggest takeaways from DIA 2024  

Share This Article